NCT01013181已完成不适用
Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Real-life " : Result of the French Experience in 72 Adults
Henri Mondor University Hospital0 个研究点目标入组 100 人开始时间: 2008年1月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 主要终点
- Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP)
研究概览
简要总结
The purpose of this study is to review the charts of the first 100 patients included in the french compassionate program including patients with Immune Thrombopenia receiving romiplostim.
详细描述
Inclusion Criteria:
- Subject has a diagnosis of ITP according to the American Society of Hematology guidelines (George et al., 1996).
- Subject is equal to or greater than 18 years of age.
- Before any study-specific procedure, the appropriate written informed consent must be obtained.
- Subject receiving romiplostim in the compassionate program
- Available follow-up of one-year
Exclusion Criteria:
•Secondary ITP e.g: thrombopenia related to hepatitis C, HIV, Chronic Lymphocytic Leukemia...
The goal of this study is to review retrospectively the charts of the 100 first patients including in this program in France during the period of January 2008 and July 2008.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria:
- •Subject has a diagnosis of ITP according to the American Society of Hematology guidelines (George et al., 1996).
- •Subject is equal to or greater than 18 years of age.
- •Before any study-specific procedure, the appropriate written informed consent must be obtained.
排除标准
- •Exclusion Criteria:
- •Secondary ITP
结局指标
主要结局
Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP)
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)ThrombocytopeniaIdiopathic Thrombocytopenic PurpuraNCT00116688Amgen313
已完成
2 期
Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)Idiopathic Thrombocytopenic PurpuraNCT00111475Amgen45
已完成
2 期
Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)MDSMyelodysplastic SyndromesRefractory CytopeniasThrombocytopeniaNCT00303472Amgen72
尚未招募
4 期
se of platelet-improving medicine Romiplostim in Liver Transplant PatientCTRI/2024/04/066269Amrita School of Pharmacy
已完成
3 期
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITPThrombocytopenic PurpuraThrombocytopeniaIdiopathic Thrombocytopenic PurpuraNCT00508820Amgen407